Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lupin Limited ( (IN:LUPIN) ) just unveiled an update.
Lupin Limited announced that the U.S. FDA conducted a Pre-Approval Inspection at its Somerset, New Jersey manufacturing facility, which concluded with one observation. The company is committed to addressing the observation promptly to ensure compliance with CGMP standards, reflecting its dedication to maintaining high-quality manufacturing practices.
More about Lupin Limited
Lupin Limited is a pharmaceutical company that operates in the healthcare industry, focusing on the development, manufacture, and marketing of a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The company has a significant market presence in the United States, India, and other global markets.
Average Trading Volume: 20,300
Technical Sentiment Signal: Buy
Current Market Cap: 894.1B INR
Find detailed analytics on LUPIN stock on TipRanks’ Stock Analysis page.